Sanofi booked €26 million ($31 million) from the drug in the first three months of the year, with Regeneron recording $69 million in sales, although the partners both think that Libtayo as the ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Its Eylea franchise showed 2% growth at $1.495 billion. Libtayo rose 50% to reach $367 million. Sanofi collaboration revenues were $1.213 billion. This represents Regeneron’s Dupixent share.

While Sanofi records sales ... which currently comprises Libtayo. Growth in Libtayo’s sales has also boosted the top line in recent quarters. Libtayo sales are being driven by growth in demand ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

It sells Libtayo, a cancer drug that recently got approved for a new medical indication. Both drugs are sold through a partnership with Sanofi. In February 2023, it also saw its Eylea drug approved ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to ...

April 24 (Reuters) - France's Sanofi (SASY.PA), opens new tab reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug ...